Cantargia (CANTA.ST) Stock Analysis & AI Equity Report
Cantargia (CANTA.ST) overview
Cantargia (CANTA.ST) stock analysis and AI equity research. For the latest completed financial year, 2024, Cantargia reported revenue of SEK 0m and operating profit of SEK -169m; the year-end share price was 1.69 SEK and market capitalisation was SEK 310m. Cantargia is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Cantargia's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-09-05. Data will be refreshed during report generation.
About Cantargia
Cantargia AB (publ) is a Swedish biotechnology company developing antibody-based treatments targeting IL1RAP. Its lead oncology program, nadunolimab (CAN04), is in clinical development for cancers including pancreatic, lung, and triple-negative breast cancer. The company also has programs for inflammatory and autoimmune diseases, and CAN10 was acquired by Otsuka Pharmaceutical in 2025.
Generate the Cantargia report
Cantargia is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Cantargia and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.